Art

J-GLOBAL ID：200902244115614000   Reference number：08A1093264

Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission

臨床的寛解期の関節リウマチ患者におけるインフリキシマブの中止

Author (4)： NAWATA Masao (Univ. Occupational and Environmental Health, Fukuoka, JPN) ,  SAITO Kazuyoshi (Univ. Occupational and Environmental Health, Fukuoka, JPN) ,  NAKAYAMADA Shingo (Univ. Occupational and Environmental Health, Fukuoka, JPN) ,  TANAKA Yoshiya (Univ. Occupational and Environmental Health, Fukuoka, JPN)
Material： Modern Rheumatology  (Mod Rheumatol)
Volume： 18  Issue： 5  Page： 460-464  Publication year： 2008 
JST Material Number： L5142A  ISSN： 1439-7595  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *rheumatoid arthritis ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08A1093264&from=J-GLOBAL&jstjournalNo=L5142A") }}

JST classification (2)： Clinical application of anti-inflammatory drugs  (GW15020E) ,  Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D)

Substance index (1)： Methotrexate

Reference (16)：

• OLSEN, NJ. New drugs for rheumatoid arthritis. N Engl J Med. 2004, 350, 2167-2179
• O'DELL, JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004, 350, 2591-2602
• STEINMAN, L. Immune therapy for autoimmune diseases. Science. 2004, 305, 212-216
• FIRESTEIN, GS. The T cell cometh : interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004, 114, 471-474
• MAINI, R. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate : a randomized phase III trial. ATTRACT Study Group. Lancet. 1999, 354, 1932-1939

Terms in the title (5)： 臨床的寛解 ,  関節リウマチ ,  患者 ,  インフリキシマブ ,  中止